GameChangers: Hypertensive Urgency

GameChangers: Hypertensive Urgency

Hypertensive urgency – asymptomatic patients with elevated blood pressure – is frequently treated in the hospital and outpatient setting. Join host, Geoff Wall, as he critically examines the evidence to assess risk over benefit.

THE GAMECHANGER: Treatment of asymptomatic hypertension has not been shown to improve clinical outcomes. Recent data highlights the risk with increased mortality through aggressive management.

Upon successful completion of this course, learners should be able to:
1. Explain the difference between hypertensive urgency and emergency
2. Discuss recent data about the possible harms of treating asymptomatic hypertension in the hospital setting

Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences

Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.  

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: October 23, 2023
Planned Expiration Date: October 23, 2024

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

Universal Activity Number (UAN): 0107-0000-23-330-H01-P
Application-based CPE Activity

CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at

¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.

Additional information


0h 30m

Topic Designator

Disease State/Drug Therapy



ACPE Topic

01 Drug Therapy





Release Date






ACPE Number


This course is in our subscription.